FDA Grants Orphan Drug Status to New CD38 Antibody Redirecting Molecule (ARM) Myeloma Therapy
Posted: Sep 18, 2020
FDA Grants Orphan Drug Status to New CD38 Antibody Redirecting Molecule (ARM) Myeloma Therapy image

The FDA has granted Orphan Drug designation to a new type of myeloma therapy called an Antibody Redirecting Molecule (ARM) targeting CD38. The orphan drug designation approval is provided to diseases that affect fewer than 200,000 people in the United States and it helps accelerate clinical development. It also provides a longer period of exclusive marketing if the drug becomes approved. 

The anti-CD38 therapy is called KP1237 and is being developed by Kleo Pharmaceuticals. The antibody-redirecting molecules (ARMs) are bispecific, meaning they go after two targets. They are engineered with modular components that are readily interchangeable, giving the platform tremendous flexibility and rapid development times. ARMs are smaller than biologic therapies, which allows for enhanced tumor/tissue penetration, reduced immune system response (daratumumab can lower normal natural killer cell function), administration of higher dose levels with improved safety profiles, and the potential to develop oral drug administration. The ARM platform is also being used to redirect NK cell-based therapies to disease targets without chimeric engineering (the CAR T cell engineering process).

Two other myeloma treatments in today's armamentum target CD38 – daratumumab and isatuximab – but patients can become refractory to these drugs over time. The KP1237 product is being evaluated for two types of myeloma patients:

  • Myeloma patients who relapsed after using daratumumab
  • Newly diagnosed myeloma patients who are MRD positive following a transplant (in this case the drug will be combined with the patient's own natural killer cells)
  • Use of KP1237 in combination with donor natural killer cells

Clinical trials for these three groups hope to open in late 2020. 

“We are pleased to receive this Orphan Drug designation for KP1237, which is advancing to Phase 1 clinical testing in the fourth quarter of 2020,” said Doug Manion, MD, CEO of Kleo Pharmaceuticals. “Based on compelling preclinical data, we will evaluate KP1237 in potentially three different clinical programs where KP1237 can have the greatest impact in patients whose options may be severely limited.”

 

We already know that daratumumab and isatuximab have been game-changers in myeloma treatment and look forward to watching this new approach develop for multiple myeloma patients.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811